All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the Lymphoma Hub was pleased to speak with Anna Sureda, Catalan Institute of Oncology, Barcelona, Spain. We asked, What role is there for allogeneic stem cell transplant in the treatment of Hodgkin lymphoma?
What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?
Sureda begins by outlining some important considerations for allogeneic hematopoietic stem cell transplant such as the use of haploidentical donors. She highlights that the introduction of new drugs like brentuximab have had an impact on reducing the number of allogenic transplants occurring. Finally, she discusses how a better knowledge of how to combine checkpoint inhibitors with allogenic stem cell transplants has led to improvements in the long term outcome of patients.
Management of patients with CLL after venetoclax discontinuation
Results from a study addressing the optimal treatment regimen after discontinuation of venetoclax and the impact of venetoclax resistance on the efficacy of subsequent therapies.
Progress in immunotherapy for hematologic malignancies
Immunotherapy has long been part of the armamentarium of therapies for hematologic malignancies. One of the first applications of immunotherapy was the use of allogeneic stem cell transplantation...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox